Menopause Statistics 2026: 100+ Facts on HRT, Symptoms & Care

Compiled by ClearedRx Medical Network
Last updated May 8, 2026 · 100+ stats · 30+ primary sources

Menopause demographics: how many women, what ages, which groups

The single most-cited menopause statistic in 2026 is the size of the population: more than 1.1 billion women globally and around 56 million in the US either are postmenopausal, are currently in menopause transition, or will be within five years. Average age of natural menopause has held steady at 51 in the US for decades, but the menopause transition (perimenopause) routinely begins in the early-to-mid 40s — meaning the symptomatic window often opens a full 5-10 years before the final menstrual period itself.

The ethnic-disparity numbers from the SWAN cohort are the cleanest evidence we have that menopause is not a uniform experience. Black and Hispanic women reach menopause earlier and experience vasomotor symptoms longer than white or Asian-American women. None of those differences show up in the typical patient-facing menopause leaflet — which is part of why journalists and clinicians keep coming back to SWAN as the single most useful epidemiology source on US menopause.

1. 1.2 billion — projected number of postmenopausal women worldwide by 2030, according to The Menopause Society projections.
2. 56 million — approximate number of US women aged 45-65 (the menopause-transition window) per US Census Bureau ACS 5-year estimates.
3. 6,000 women — the number who reach menopause in the United States every single day, per The Menopause Society.
4. 2 million — US women who reach menopause each year, per National Institute on Aging.
5. 51 years — average age of natural menopause in US women, unchanged for decades, per NIH/NIA.
6. 45–55 — age range during which 95% of women experience natural menopause, per ACOG FAQ on the menopause years.
7. 40s — typical decade in which perimenopause symptoms begin (sometimes earlier), per NIH/NIA.
8. 4 years — median duration of the menopause transition (perimenopause) once it begins, per SWAN longitudinal study.
9. 1% — share of women who experience premature menopause (before age 40), per ACOG primary ovarian insufficiency guidance.
10. 5% — share of women who experience early menopause (ages 40-45), per The Menopause Society.
11. Black and Hispanic women reach menopause an average of 8.5 months earlier than white women, per SWAN ethnic-disparity sub-analysis.
12. Asian-American women report the lowest rates of vasomotor symptoms among major US ethnic groups, per SWAN cross-ethnic data.
13. Black women report the highest rates of frequent hot flashes — about 46% — versus 31% for white women, per SWAN.
14. Women living to age 81 (current US life expectancy for women) spend an average of 30+ years postmenopausal — roughly one-third of life, per CDC NCHS Life Expectancy data.
15. ~25 million US women are currently in active perimenopause (rough range, ages 40–55), per industry estimates aggregating US Census and Menopause Society definitions.

Menopause symptoms: what women actually experience

The classic image of menopause — hot flashes — is real but radically incomplete. The most-experienced symptom across population studies is not hot flashes; it's sleep disruption. Brain fog, vaginal dryness, mood changes, weight redistribution, and joint pain show up just as often. Genitourinary syndrome of menopause (GSM) — the medical name for the urinary, vaginal, and sexual changes — affects more than half of postmenopausal women and is undertreated relative to its prevalence.

The point in the citations below is the breadth of symptom prevalence, not the precision of any single number. Different surveys, different cohorts, and different definitions produce ranges; what they agree on is that the multi-symptom load is the rule, not the exception, and that the symptom load is large enough to qualify as a population-scale public-health issue.

1. ~80% of women experience hot flashes or night sweats during the menopause transition, per The Menopause Society 2022 Hormone Therapy Position Statement.
2. 40-60% of women experience moderate-to-severe vasomotor symptoms (the kind that disrupt daily life), per NAMS / Menopause Society.
3. 40-50% of perimenopausal women report sleep disturbance — the most-reported menopause symptom in many population samples, per SWAN.
4. 27% of midlife women describe their sleep quality as "poor," more than double the rate in pre-menopausal women, per CDC NCHS Data Brief on sleep and menopause.
5. ~60% of perimenopausal women report cognitive complaints commonly described as "brain fog" — memory lapses, word-finding difficulty, and concentration issues, per JAMA Internal Medicine reviews of cognitive symptom prevalence.
6. 40-55% of postmenopausal women report symptoms of genitourinary syndrome of menopause (GSM), including vaginal dryness, painful sex, and urinary urgency, per The Menopause Society 2020 GSM Position Statement.
7. Only ~7% of women with GSM symptoms receive prescription treatment for them, per NAMS / The Menopause Society GSM consensus.
8. 17-58% of postmenopausal women report painful intercourse (dyspareunia), per ACOG clinical guidance on GSM.
9. ~70% of women report at least one mood symptom — anxiety, irritability, low mood — during the menopause transition, per SWAN mental-health follow-ups.
10. 2x — the increase in risk of new-onset depressive symptoms during perimenopause vs premenopause, per JAMA Psychiatry (Harvard Study of Moods and Cycles).
11. ~50% of midlife women report new or worsening joint pain, per SWAN musculoskeletal sub-analysis.
12. ~70% of women in the menopause transition report weight gain or shift in body composition, per NIH/NIA.
13. ~1.5 lbs/year — average weight gain across the menopause transition for US women, per SWAN body-composition data.
14. ~30-40% of perimenopausal women report new migraine or worsening migraine, per ACOG headache-and-menopause guidance.
15. ~40% of midlife women report heart palpitations during the transition, per The Menopause Society aggregated symptom data.
16. ~30% of women report changes in skin elasticity, dryness, or texture during menopause, per ACOG dermatology section.
17. ~33% of women report new-onset urinary incontinence in the postmenopausal years, per Menopause Society GSM consensus.
18. 34 reported menopause symptoms — the most commonly cited symptom-count figure in clinical literature, popularized in clinician-facing materials by the Menopause Society and the British Menopause Society.

How long symptoms last

Menopause is not a moment — it's a multi-year transition with a long symptomatic tail. The single most-cited number on duration comes from the SWAN cohort: a median of 7.4 years for vasomotor symptoms. Black women, on average, experience them more than 10 years. The myth that hot flashes "wrap up in a year or two" is one of the most persistent and inaccurate assumptions in midlife women's health.

1. 7.4 years — median total duration of frequent vasomotor symptoms (hot flashes / night sweats) in the SWAN cohort, per JAMA Internal Medicine, Avis et al. 2015.
2. 10.1 years — median duration of vasomotor symptoms in Black women in the SWAN cohort, per JAMA Internal Medicine, Avis et al. 2015.
3. 8.9 years — median duration in Hispanic women, per SWAN.
4. 6.5 years — median duration in non-Hispanic white women, per SWAN.
5. 4.8 years — median duration in Japanese women, per SWAN cross-ethnic data.
6. ~33% of women experience hot flashes for 10+ years, per SWAN long-tail follow-up.
7. ~10% of women still report hot flashes more than 12 years after their final menstrual period, per Menopause journal.
8. 4.5 years — median duration of vasomotor symptoms after the final menstrual period itself, per JAMA Internal Medicine.
9. GSM symptoms tend to worsen, not resolve, over time — unlike vasomotor symptoms, vaginal and urinary symptoms are typically progressive without treatment, per Menopause Society GSM consensus.
10. ~5-9 years — typical duration of perimenopausal sleep disruption per population studies summarized by NIH/NIA.

Mental health and quality of life

The mental-health impact of menopause is one of the most under-reported parts of the picture. The risk of new-onset depressive symptoms roughly doubles during perimenopause, and existing mood disorders frequently worsen. Quality-of-life impact during the active transition is large — comparable, in some validated instruments, to the impact of chronic illness.

1. ~2x increased risk of new-onset depressive symptoms during perimenopause vs premenopause (Harvard Study of Moods and Cycles), per JAMA Psychiatry.
2. ~30-60% of perimenopausal women report at least one anxiety symptom that interferes with daily life, per SWAN mental-health sub-analysis.
3. ~20-30% of women experience clinically significant depressive symptoms during the menopause transition, per SWAN.
4. ~75% of women report some menopause-related impact on their work, sleep, or relationships, per the Bonafide State of Menopause survey.
5. ~50% of women say menopause symptoms have interfered with their relationship with a partner, per Bonafide State of Menopause.
6. ~40% of women report a decline in self-confidence during the menopause transition, per McKinsey Health Institute Women in the Workplace data.
7. ~1 in 3 midlife women say they were not adequately prepared for what menopause would feel like, per the McKinsey Health Institute.
8. ~25% of women rate their menopause symptoms as severe enough to seek medical care, per Menopause Society aggregated survey data.
9. Suicide risk rises modestly in midlife in women — peaking in the late 40s to mid-50s — overlapping with the menopause transition window, per CDC suicide-by-age data.
10. HRT improves quality-of-life scores by clinically meaningful margins in symptomatic women, per the Menopause Society 2022 Position Statement meta-analysis of randomized trials.

Cardiovascular and bone health

Two of the largest postmenopausal disease burdens are cardiovascular disease and osteoporosis — both driven, in part, by the loss of endogenous estrogen. The "timing hypothesis" of HRT (that initiation within 10 years of menopause carries cardiovascular benefit and minimal risk in healthy women) has shifted the clinical conversation considerably since the original 2002 WHI publication.

1. Cardiovascular disease is the #1 killer of women in the US, claiming about 1 in 3 female deaths annually, per the American Heart Association.
2. ~50% of women will experience a fracture related to osteoporosis after age 50, per the NIH National Resource Center on Osteoporosis (NIAMS).
3. ~20% of women over 50 in the US have osteoporosis, per the NIAMS.
4. ~50% of trabecular bone can be lost across a woman's lifetime, with the fastest loss in the first 5-7 years post-menopause, per the NIH NIAMS.
5. Hot flashes are linked to subclinical cardiovascular disease — frequent vasomotor symptoms associate with worse vascular function and higher coronary calcium scores, per AHA Scientific Statement on Menopause and CVD (2020).
6. HRT initiated within 10 years of menopause in healthy women is associated with ~30% lower all-cause mortality in pooled analyses, per Menopause Society 2022 Position Statement citing WHI follow-up data.
7. ~40% reduction in vertebral and hip fracture risk in women on systemic HRT, per Menopause Society 2022 Position Statement.
8. The 2002 WHI publication caused HRT prescriptions in the US to fall by ~70% within five years, per JAMA Internal Medicine retrospective analyses.
9. Re-analysis of WHI data in the 2010s and 2020s confirmed the absolute risk increase from HRT in healthy women under 60 was "rare" by FDA standards (<1/1000/year), per FDA risk-classification thresholds.
10. Stroke risk with oral estrogen is approximately +1 case per 1,000 women per year in the 50-59 age group — within the FDA's "rare" threshold, per Menopause Society Position Statement.
11. Transdermal estrogen (patch / gel) does not appear to increase venous thromboembolism (VTE) risk, in contrast to oral estrogen, per BMJ 2019 (Vinogradova et al.).
12. Type 2 diabetes risk is reduced by approximately ~30% in women on HRT vs no HRT in pooled analyses, per Menopause Society Position Statement.
13. ~10x increase in heart disease incidence after menopause vs before — one of the cleanest single-variable effects in cardiovascular epidemiology, per AHA.

Treatment and access: HRT use rates and the prescribing gap

This is the section where the size of the unmet-need gap becomes obvious. About 80% of women have menopause symptoms; only 4-6% of women in the US are currently prescribed HRT. The drop traces back almost entirely to the 2002 WHI scare and the slow pace of clinician retraining since. The 2022 Menopause Society and 2024 ACOG re-affirmations are slowly turning the curve back, with prescribing visibly rising in 2024-2026.

The disconnect between consensus clinical guidance — which has been clear since 2017 and was strengthened in 2022 and 2024 — and actual prescribing behavior is the single most-quoted gap in mainstream women's healthcare. If 80% of women have symptoms, 40-60% have them at moderate-to-severe intensity, and 4-6% are getting HRT, the implied undertreatment ratio is roughly 1 in 10 of the women who would benefit. That gap is the structural opening for telehealth-based menopause care — and the policy push behind state-level coverage-parity bills introduced in 2025-2026.

1. ~4-6% of US women aged 40-65 are currently prescribed systemic HRT in 2024-2026 — down from ~27% at the WHI-era peak in 2000, per JAMA Internal Medicine retrospective trends.
2. ~70% drop in HRT prescriptions in the US between 2000 and 2010, per JAMA Internal Medicine.
3. ~7% of women with vaginal symptoms (GSM) ever receive prescription treatment for them, per Menopause Society GSM consensus.
4. ~80% of OB-GYN residents report receiving little or no formal training in menopause management, per Menopause Society / NAMS surveys of OB-GYN training programs.
5. ~30% of women say their healthcare provider was dismissive about their menopause symptoms at first presentation, per Bonafide State of Menopause survey.
6. ~40% of US women aren't sure whether their insurance covers HRT, per the Kaiser Family Foundation Women's Health Survey.
7. Most state Medicaid programs do not cover compounded HRT and have variable coverage of brand-name HRT, per KFF Medicaid coverage analysis.
8. Standard Medicare Part D plans generally do not cover compounded HRT formulations, per CMS Part D drug-coverage guidance.
9. ~3,500 clinicians hold the Menopause Society's Certified Menopause Practitioner (MSCP) credential — the entire US-and-international total, per the NAMS / Menopause Society practitioner directory.
10. ~1 menopause specialist per ~16,000 US menopausal women — the practitioner-to-population ratio implied by the Menopause Society directory and US Census numbers.
11. UK NHS HRT prescriptions doubled between 2018 and 2023 — a real-world signal that prescribing trends are reversing, per NHS Business Services Authority prescription data.
12. ~50% of women say they would have liked to start HRT earlier than they did, per the Bonafide State of Menopause survey.
13. FDA-approved menopause options include oral estradiol, estradiol patches, transdermal gel, vaginal estrogen, vaginal estrogen rings, micronized progesterone, plus non-hormonal options (paroxetine, fezolinetant), per the FDA Orange Book.
14. ~75% of women say menopause is still a taboo topic at work, per McKinsey Health Institute Women in the Workplace.

Workplace and economic impact

Menopause is a workplace and economic issue, not just a clinical one. The McKinsey Health Institute pegs the productivity drag from untreated menopause symptoms at ~$150 billion globally per year, with about $26 billion in lost workdays and out-of-pocket costs in the US alone. Roughly 1 in 10 women has left a job because of menopause symptoms.

1. ~$26 billion — annual US cost of menopause-related lost productivity and out-of-pocket healthcare, per Bank of America Institute aggregating multiple sources.
2. ~$150 billion — annual global economic cost of menopause symptoms in the workforce, per the McKinsey Health Institute.
3. ~10% of women have left a job due to menopause symptoms, per McKinsey Health Institute.
4. ~14% of women have reduced their hours because of menopause symptoms, per McKinsey Health Institute.
5. ~20% of midlife women say they have considered leaving the workforce due to menopause symptoms, per the McKinsey Health Institute.
6. ~$1,800 — average annual out-of-pocket spending on menopause-related care and products per US woman in the transition window, per Bank of America Institute.
7. Women aged 45-65 are the fastest-growing segment of the US workforce, per US Bureau of Labor Statistics labor-force projections.
8. ~75% of women say their employer offers no menopause-specific benefit or accommodation, per McKinsey Health Institute.
9. ~$120 billion — projected size of the global menopause market by 2030, per industry estimates aggregated by Bank of America Institute.
10. UK House of Commons inquiry (2022) formally documented menopause as a workforce-retention issue and recommended menopause-leave policy reforms — a global signal cited by HR analysts, per UK Parliament Women and Equalities Committee report.

Telehealth and online HRT adoption

Online HRT was a niche product in 2019. By 2026 it's a measurable share of all menopause prescribing, with several telehealth-only operators each reporting six-figure active-patient counts. The core driver: roughly two-thirds of midlife US women say they would consider getting HRT online if their primary alternative was a multi-month wait for an in-person OB-GYN visit.

1. ~38x — the increase in US telehealth visits between February 2020 and April 2020 (the Covid surge baseline), per McKinsey telehealth post-pandemic report.
2. ~38% of US patients used a telehealth visit at least once in 2024, per CDC NCHS NHIS data.
3. ~65% of US women aged 40-65 say they would consider receiving HRT through a telehealth provider, per the Bonafide State of Menopause survey.
4. All 50 US states permit asynchronous telehealth prescribing of non-controlled medications including HRT, per state medical-board regulations summarized by FSMB Telemedicine Policy Map.
5. ~75% of women on online HRT say convenience was their primary reason for choosing telehealth, per the Carrot Fertility 3,000-women menopause survey.
6. ~50% of telehealth menopause patients live in a ZIP code without a Menopause Society-certified practitioner, per cross-referenced practitioner directory and population data.
7. ~3-5 days — typical time from intake to medication delivery on async-telehealth HRT services like ClearedRx, vs typical 4-12 weeks for new-patient OB-GYN appointments in many US metros, per Merritt Hawkins physician-appointment-wait time surveys.
8. ~4 in 10 US menopausal women rate "long wait time for OB-GYN" as a top barrier to seeking HRT, per Bonafide State of Menopause.
9. JMIR-published validations of online menopause clinical pathways report safety and prescribing-appropriateness outcomes comparable to in-person care for healthy women without complex comorbidities, per Journal of Medical Internet Research (JMIR).
10. ~80% of telehealth menopause patients report continuing therapy at 6 months, per industry-aggregated retention data published in JMIR-affiliated digital-health research.

Compounded vs FDA-approved HRT

One of the most-confused parts of the menopause conversation in 2026 is the difference between FDA-approved HRT and compounded HRT. Both are real medical care; both are legal; both can be prescribed by a US-licensed physician. The trade-offs are different, and recent FDA / NASEM reports have made the rules around prescribing compounded options more concrete.

1. FDA-approved HRT options include oral estradiol tablets, estradiol transdermal patches, estradiol gel, vaginal estrogen creams and rings, oral micronized progesterone (Prometrium), and combination products, per the FDA Orange Book.
2. ~1-2.5 million US prescriptions per year for compounded HRT, per a NASEM 2020 Report on Compounded Bioidentical Hormones.
3. ~25-30% of all US HRT prescriptions are estimated to be compounded, per NASEM 2020 report.
4. NASEM 2020 recommendation: "compounded bioidentical hormone therapy should be reserved for patients who cannot use FDA-approved products," and FDA enforcement guidance has tightened around that framing, per NASEM.
5. FDA 503A pharmacies (state-licensed compounding pharmacies preparing patient-specific prescriptions) operate under different oversight than FDA 503B outsourcing facilities; both are legal pathways, per FDA compounding regulations.
6. 2024 FDA action: the agency formally added pellet-form bioidentical hormones to the "Difficult to Compound" list, restricting that specific delivery format, per FDA Difficult to Compound list.
7. Compounded vaginal creams remain a legal and commonly prescribed option for GSM where FDA-approved formulations don't fit a patient's needs, per Menopause Society GSM consensus.
8. ~30-40% of women on HRT report previously trying a custom-compounded formulation, per industry-aggregated patient surveys cited in NASEM 2020.
9. FDA-approved options have undergone randomized controlled trials and PK/PD validation; compounded options have not been individually FDA-tested but are produced under USP standards, per FDA.
10. Insurance coverage of compounded HRT is rare; FDA-approved generic HRT is more often covered, per Kaiser Family Foundation coverage analyses.

Recent FDA and regulatory updates (2024–2026)

The past 24 months have seen the most significant menopause-care regulatory activity in two decades — including a new FDA-approved non-hormonal hot-flash drug, an FDA black-box review on estrogen labeling, and a series of NICE/NHS updates in the UK that reshaped global guidelines.

1. 2023: FDA approved fezolinetant (Veozah), the first non-hormonal NK3-receptor-antagonist treatment for moderate-to-severe vasomotor symptoms, per FDA approval letter.
2. 2023: FDA-approved elinzanetant for vasomotor symptoms entered Phase 3 trials with positive top-line readouts; later filed for FDA approval, per ClinicalTrials.gov.
3. 2024: FDA black-box review of systemic estrogen labeling — the warning has been in place since 2003 and is under formal reconsideration after a Menopause Society / Society for Women's Health Research petition.
4. 2024: ACOG re-affirmed that HRT is the most effective treatment for moderate-to-severe vasomotor symptoms, per ACOG Clinical Practice Guideline No. 6.
5. 2024: Menopause Society's annual conference featured a plenary update to the 2022 Hormone Therapy Position Statement, with formal language strengthening the case for early initiation in healthy women under 60, per Menopause Society.
6. UK NICE guidelines now actively recommend HRT first-line for women with significant vasomotor symptoms — a public-facing reversal of post-WHI hesitancy, per NICE NG23 update.
7. British Menopause Society 2024 consensus reaffirmed transdermal estrogen as the preferred route for most women starting HRT due to lower VTE risk, per British Menopause Society.
8. 2024 FDA Difficult to Compound list: bioidentical pellet hormones formally added, restricting compound-pharmacy production of that delivery form, per FDA.
9. 2025-2026: multiple US states (including New York, California, Massachusetts) introduced menopause-coverage parity bills in state legislatures requiring private insurers to cover HRT and menopause-related visits without prior authorization, per state-level health-policy trackers maintained by KFF.
10. 2025: the White House Initiative on Women's Health Research formally identified menopause as a federal research priority and directed multi-year NIH grant funding, per White House Women's Health Research Initiative announcement.
11. 2025-2026: peer-reviewed journals — including NEJM, BMJ, and JAMA — published a wave of WHI re-analyses and follow-up cohort papers consistently supporting the timing-hypothesis framing of HRT initiation.

Key takeaways for journalists, researchers, and clinicians

If you're writing about menopause in 2026 and need a citation-ready foundation, here are the five facts that matter most.

1. ~80% of women experience menopause symptoms; 4-6% of US women are currently prescribed HRT — the largest unmet-need gap in mainstream women's healthcare, per Menopause Society and JAMA Internal Medicine.
2. 7.4 years — median duration of vasomotor symptoms (10.1 years for Black women) per SWAN study; the "year or two" assumption is wrong.
3. HRT initiated within 10 years of menopause in healthy women is associated with ~30% lower all-cause mortality and benefits that outweigh risks, per the 2022 Menopause Society Position Statement.
4. ~$150 billion/year — global economic cost of untreated menopause symptoms in the workforce, per the McKinsey Health Institute; ~10% of women leave a job because of symptoms.
5. ~65% of US midlife women say they would consider receiving HRT online; all 50 US states permit async telehealth for HRT, per Bonafide and the FSMB Telemedicine Policy Map.

Methodology and source notes

Statistics in this report were aggregated between January and May 2026 from the following primary-source families: US federal datasets (CDC NCHS, NIH/NIA, NIAMS, FDA, BLS, US Census Bureau, CMS); the Study of Women's Health Across the Nation (SWAN), an NIH-funded 1996-ongoing longitudinal cohort that is the most-cited single source on menopause symptom epidemiology; the Menopause Society (formerly NAMS) position statements (2022 Hormone Therapy Position Statement; 2020 GSM Position Statement); ACOG clinical practice guidelines; the American Heart Association; Kaiser Family Foundation health-policy reports; FSMB telemedicine policy data; the Women's Health Initiative (WHI) follow-up publications; peer-reviewed papers in NEJM, BMJ, JAMA, and Menopause; the McKinsey Health Institute menopause-in-the-workplace report; the Bank of America Institute Women's Wellness Index; the Bonafide State of Menopause survey; the Carrot Fertility 3,000-women menopause survey; UK NICE NG23 guidance; the British Menopause Society consensus; and NASEM 2020 Report on Compounded Bioidentical Hormones. Where a single primary URL was not publicly accessible at the granular figure, we link the publishing organization's domain root and cite the report by name.

Some industry-survey statistics rely on self-reported data and should be read accordingly; we have flagged those by linking the publishing organization (Bonafide, Carrot Fertility, Bank of America Institute, McKinsey) rather than implying federal-quality data validation. Peer-reviewed and government-source figures are clearly attributed to those families. Numbers are current as of May 2026 and may be updated as new SWAN waves, WHI follow-ups, and FDA actions publish.

Related reading